+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Phenylketonuria (PKU) - Pipeline Review, H1 2019

  • ID: 4750100
  • Drug Pipelines
  • 67 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Agios Pharmaceuticals Inc
  • Censa Pharmaceuticals Inc
  • Codexis Inc
  • Erytech Pharma SA
  • Generation Bio Corp
  • Homology Medicines Inc
  • MORE
Phenylketonuria (PKU) - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Phenylketonuria (PKU) - Pipeline Review, H1 2019, provides an overview of the Phenylketonuria (PKU) (Metabolic Disorders) pipeline landscape.

Phenylketonuria (also called PKU), is a rare inherited disorder that causes an amino acid called phenylalanine to build up in body. Symptoms include intellectual disability, psychiatric disorders, hyperactivity, skin rashes, poor bone strength and abnormally small head.

Report Highlights

This latest pipeline guide Phenylketonuria (PKU) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Phenylketonuria (PKU) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Phenylketonuria (PKU) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Phenylketonuria (PKU) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 12 and 1 respectively.

Phenylketonuria (PKU) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Phenylketonuria (PKU) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Phenylketonuria (PKU) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Phenylketonuria (PKU) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Phenylketonuria (PKU) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Phenylketonuria (PKU) (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Phenylketonuria (PKU) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Phenylketonuria (PKU) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Agios Pharmaceuticals Inc
  • Censa Pharmaceuticals Inc
  • Codexis Inc
  • Erytech Pharma SA
  • Generation Bio Corp
  • Homology Medicines Inc
  • MORE
Introduction

Report Coverage

Phenylketonuria (PKU) - Overview

Phenylketonuria (PKU) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Phenylketonuria (PKU) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Phenylketonuria (PKU) - Companies Involved in Therapeutics Development

Agios Pharmaceuticals Inc

American Gene Technologies International Inc

BioMarin Pharmaceutical Inc

Censa Pharmaceuticals Inc

Codexis Inc

Erytech Pharma SA

Generation Bio Corp

Homology Medicines Inc

MipSalus ApS

Moderna Therapeutics Inc

Rubius Therapeutics Inc

Synlogic Inc

Synthetic Biologics Inc

Ultragenyx Pharmaceutical Inc

Phenylketonuria (PKU) - Drug Profiles

BMN-307 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-6114 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Phenylketonuria - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNSA-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Phenylketonuria and Progressive Familial Intrahepatic Cholestasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Phenylalanine Hydroxylase for Phenylketonuria - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMI-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMI-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mRNA-3283 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegvaliase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Phelimin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTX-134 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Phenylketonuria - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Phenylalanine Hydroxylase for Phenylketonuria - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYN-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYNB-1618 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UX-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Phenylketonuria (PKU) - Dormant Projects

Phenylketonuria (PKU) - Product Development Milestones

Featured News & Press Releases

Jan 07, 2019: Retrophin provides update on phenylketonuria drug CNSA-001

Jan 07, 2019: BioMarin highlights Palynziq at 37th Annual J.P. Morgan Healthcare Conference in San Francisco

Jan 07, 2019: Rubius Therapeutics provides update on its phenylketonuria drug candidate RTX-134 at the 37th Annual J.P. Morgan Healthcare Conference

Jan 07, 2019: Homology Medicines achieves 2018 goals and prepares PKU Gene Therapy Program for the clinic with initial data expected in 2019

Jan 07, 2019: Homology Medicines advances first gene editing development candidate into IND-enabling studies for pediatric patients with phenylketonuria

Nov 08, 2018: Codexis announces results of phase 1a clinical trial with CDX-6114

Nov 07, 2018: BioMarin provides update on Palynziq at at R&D Day in New York

Nov 07, 2018: BioMarin provides update on BMN 307, a pre-clinical gene therapy for PKU

Oct 18, 2018: American Gene Technologies granted FDA orphan drug designation for phenylketonuria

Oct 18, 2018: Homology Medicines Presents Long-Term Efficacy Data of a Single Dose of Gene Therapy Development Candidate for Treatment of Phenylketonuria

Jul 11, 2018: Codexis Appoints Dr. Hicham Alaoui, Veteran Drug Discoverer, as Vice President, Biotherapeutics Research & Development

Jul 09, 2018: Codexis Doses First Subjects in Phase 1a Trial of CDX-6114

Jul 05, 2018: Homology Medicines to present at the National PKU Alliance Conference

May 24, 2018: BioMarin Receives Standard Approval for Palynziq (pegvaliase-pqpz) Injection for Treatment of Adults with Phenylketonuria (PKU), a Rare Genetic Disease

May 18, 2018: Homology Medicines Presents Data from PKU Gene Therapy Program Demonstrating Long-Term Durability of Treatment in IND-Enabling Studies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Phenylketonuria (PKU), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Phenylketonuria (PKU) - Pipeline by Agios Pharmaceuticals Inc, H1 2019

Phenylketonuria (PKU) - Pipeline by American Gene Technologies International Inc, H1 2019

Phenylketonuria (PKU) - Pipeline by BioMarin Pharmaceutical Inc, H1 2019

Phenylketonuria (PKU) - Pipeline by Censa Pharmaceuticals Inc, H1 2019

Phenylketonuria (PKU) - Pipeline by Codexis Inc, H1 2019

Phenylketonuria (PKU) - Pipeline by Erytech Pharma SA, H1 2019

Phenylketonuria (PKU) - Pipeline by Generation Bio Corp, H1 2019

Phenylketonuria (PKU) - Pipeline by Homology Medicines Inc, H1 2019

Phenylketonuria (PKU) - Pipeline by MipSalus ApS, H1 2019

Phenylketonuria (PKU) - Pipeline by Moderna Therapeutics Inc, H1 2019

Phenylketonuria (PKU) - Pipeline by Rubius Therapeutics Inc, H1 2019

Phenylketonuria (PKU) - Pipeline by Synlogic Inc, H1 2019

Phenylketonuria (PKU) - Pipeline by Synthetic Biologics Inc, H1 2019

Phenylketonuria (PKU) - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2019

Phenylketonuria (PKU) - Dormant Projects, H1 2019

List of Figures

Number of Products under Development for Phenylketonuria (PKU), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Agios Pharmaceuticals Inc
  • American Gene Technologies International Inc
  • BioMarin Pharmaceutical Inc
  • Censa Pharmaceuticals Inc
  • Codexis Inc
  • Erytech Pharma SA
  • Generation Bio Corp
  • Homology Medicines Inc
  • MipSalus ApS
  • Moderna Therapeutics Inc
  • Rubius Therapeutics Inc
  • Synlogic Inc
  • Synthetic Biologics Inc
  • Ultragenyx Pharmaceutical Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4750100
Adroll
adroll